Clinical trial
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
NCT00265655 · Agennix, Industry · Completed
Key facts
| NCT number | NCT00265655 |
|---|---|
| Title | Satraplatin for Patients With Metastatic Breast Cancer (MBC) |
| Official title | Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC) |
| Lead sponsor | Agennix, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Satraplatin |
| Enrollment | 40 |
| Start date | Nov 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Dec 15, 2005 |
| Last update posted | Mar 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: